Familial dysfibrinogenemia: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
(2 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
{{SK}} Dysfibrinogenemia, familial | |||
==Overview== | ==Overview== | ||
Line 14: | Line 16: | ||
*'''Wiesbaden''' is a major defect, there is aggregation of fibrin monomers, the thrombin time is prolonged, there is an inhibitory effect on normal clotting and there is both bleeding and thrombosis. | *'''Wiesbaden''' is a major defect, there is aggregation of fibrin monomers, the thrombin time is prolonged, there is an inhibitory effect on normal clotting and there is both bleeding and thrombosis. | ||
==References== | |||
{{reflist|2}} | |||
Latest revision as of 19:39, 21 September 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: Dysfibrinogenemia, familial
Overview
The dysfibrinogenemias are a group of autosomal dominant disorders of qualitatively abnormal fibrinogens. There are various different fibrinogen abnormalities, each named after the place where it was discovered. Each dysfibrinogenemia is associated with slightly different effects on the thrombin time and on normal clotting.
Classification
Some dysfibrinogenemias cause abnormal bleeding or even thrombosis, while others have no affect on either bleeding or thrombosis. Some examples are;
- Amsterdam is a major defect, characterized by aggregation of fibrin monomers, prolonged thrombin time, and an inhibitory effect on normal clotting - but it is asymptomatic.
- Detroit is a major defect, there is fibrinopeptide release, the thrombin time is prolonged, there is an inhibitory effect on normal clotting and there is abnormal bleeding.
- Wiesbaden is a major defect, there is aggregation of fibrin monomers, the thrombin time is prolonged, there is an inhibitory effect on normal clotting and there is both bleeding and thrombosis.